22:05 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) In vitro and mouse studies suggest AGRN could help treat MI. In a mouse model of MI, a single intracardial injection of AGRN decreased scar formation and increased cardiomyocyte proliferation and cardiac...
07:00 , Mar 26, 2012 |  BC Week In Review  |  Company News

Neurotune sales and marketing update

Neurotune launched NTCAF ELISA to diagnose sarcopenia. The ELISA-based diagnostic for detection of 22kDa C-terminal agrin fragment (CAF) in human serum was developed in collaboration with MicroCoat Biotechnologie GmbH (Bernried, Germany) and the...
08:00 , Nov 18, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Agrin (AGRN) Rat studies identified an acetaminophen analog that increased agrin expression to help treat neuropathic...
07:00 , Sep 24, 2001 |  BC Week In Review  |  Company News

Novartis other research news

Researchers published in Nature that transgenic expression of an agrin minigene that encodes the laminin and alpha-dystroglycan binding sites in a mouse model of muscular dystrophy improved locomotor activity and inhibited muscle fiber degeneration compared...
08:00 , Dec 16, 1996 |  BioCentury  |  Strategy

Regeneron's P & G deal

Although Procter & Gamble Co. isn't the most obvious partner for the biotech industry, the consumer products company is teaming up with Regeneron Pharmaceuticals Inc. (REGN) to develop therapeutics for muscle diseases and disorders. The...
07:00 , May 20, 1996 |  BC Week In Review  |  Company News

Regeneron other research news

REGN researchers and colleagues have elucidated a portion of the communication system between nerves and muscles, which should aid in the study of the muscle deterioration that accompanies muscular dystrophies, motor neuron disease and myasthenia...
07:00 , Aug 1, 1994 |  BC Week In Review  |  Company News

Khepri other research news

The South San Francisco company received two Phase I SBIR grants to develop drugs for wound healing and neurologic diseases based on proteases and protease inhibitors. A $67,000 grant from the NIH's Arthritis and...